Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
AssigneeDana-Farber Cancer Institute, Inc.
InventorsWayne A. MARASCO, Quan ZHU, De-Kuan CHANG
Life of this patent
Estimating the term…
Abstract
The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
Claims26
An isolated humanized monoclonal antibody that binds to the human CC chemokine receptor 4 (CCR4) and has an IgG4 heavy chain constant region.
Dependencies are inferred from the claim text.